Source-grounded facts extracted from Dare Bioscience, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Dare Bioscience, Inc. reported financial results for the year ended December 31, 2025.
“On March 26, 2026, Daré Bioscience, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2025, a copy of which is furnished as Exhibit 99.1 to this report.”
Dare Bioscience, Inc.: Filed Certificate of Designation designating 4,999,620 shares as Series A Convertible Preferred Stock, establishing powers, preferences, and rights (effective 2026-01-23).
“On January 23, 2026, in anticipation of the initial closing of the Offering (as defined below), Daré Bioscience, Inc. (“Daré” “we,” “us,” or “our”) filed a Certificate of Designation of Series A Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware, which became effective upon filing.”
Dare Bioscience, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
“February 13, 2025, Nasdaq’s Listing Qualifications Department (the “Staff”) notified the Company that because the Company did not timely regain compliance with the Minimum MVLS Rule by February 10, 2025, the Company’s co”
Dare Bioscience, Inc. reported financial results for the quarter ended March 31, 2024.
“Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the quarter ended March 31, 2024, a copy of which is furnished as Exhibit 99.1 to this report.”
Dare Bioscience, Inc. entered into Synthetic Royalty Purchase Agreement with XOMA (US) LLC (effective 2024-04-29).
“On April 29, 2024, Daré Bioscience, Inc. (“Daré” or the “Company”) entered into a Traditional Royalty Purchase Agreement and a Synthetic Royalty Purchase Agreement (together, the “Agreements”) with XOMA (US) LLC (“XOMA”).”
Dare Bioscience, Inc. entered into Traditional Royalty Purchase Agreement with XOMA (US) LLC valued at $22.0 million (effective 2024-04-29).
“On April 29, 2024, Daré Bioscience, Inc. (“Daré” or the “Company”) entered into a Traditional Royalty Purchase Agreement and a Synthetic Royalty Purchase Agreement (together, the “Agreements”) with XOMA (US) LLC (“XOMA”). In accordance with the Agreements, on April 29, 2024, XOMA paid $22.0 million to Daré”
Dare Bioscience, Inc. reported financial results for the fiscal year ended December 31, 2023.
“On March 28, 2024, Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the fiscal year ended December 31, 2023”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.